Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

06:49
11/23/16
11/23
06:49
11/23/16
06:49

Eli Lilly's Phase 3 solanezumab clinical trial did not meet primary endpoint

Eli Lilly announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease. Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo, as measured by the ADAS-Cog14. While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small. There were no new safety signals identified in the study. Lilly will not pursue regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer's disease. Lilly will work with investigators to appropriately conclude the open-label extensions for EXPEDITION, EXPEDITION2 and EXPEDITION3. The EXPEDITION3 study outcome is expected to result in a Q4 charge of approximately $150M pre-tax, or approximately 9c per share after-tax.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

09:10
12/06/16
12/06
09:10
12/06/16
09:10
General news
U.S. equities are mostly treading water »

U.S. equities are mostly…

BWLD

Buffalo Wild Wings

$170.85

2.75 (1.64%)

09:08
12/06/16
12/06
09:08
12/06/16
09:08
Hot Stocks
Marcato launches dedicated website to express views on Buffalo Wild Wings »

Marcato Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:07
12/06/16
12/06
09:07
12/06/16
09:07
Hot Stocks
Breaking Hot Stocks news story on Belden, Digi International »

Belden…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$13.03

0.09 (0.70%)

09:06
12/06/16
12/06
09:06
12/06/16
09:06
Initiation
Huntington Bancshares initiated  »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:06
12/06/16
12/06
09:06
12/06/16
09:06
Hot Stocks
Breaking Hot Stocks news story on Belden, Digi International »

Belden: Offer for Digi…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Belden: Digi management, board 'unwilling' to engage in discussions with Belden »

Notes…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE.A

Forest City

$18.75

0.45 (2.46%)

, FCE.B

Forest City

$19.25

0.56 (3.00%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Forest City recommends shareholders to eliminate dual-class share structure »

Forest City Realty Trust…

FCE.A

Forest City

$18.75

0.45 (2.46%)

FCE.B

Forest City

$19.25

0.56 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Belden reiterates $13.82 per share offer to Digi International board »

Belden (BDC) announced…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BW

Babcock & Wilcox

$15.99

0.46 (2.96%)

09:04
12/06/16
12/06
09:04
12/06/16
09:04
Hot Stocks
B&W names D. Paul Scavuzzo Chief Commercial Officer »

Babcock & Wilcox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

XPLR

Xplore Technologies

$2.31

-0.0124 (-0.53%)

09:04
12/06/16
12/06
09:04
12/06/16
09:04
Hot Stocks
Xplore Technologies receives second rugged tablet follow-on order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BA

Boeing

$152.16

-0.09 (-0.06%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Periodicals
Trump wants to cancel Boeing Air Force One order »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLJ

RLJ Lodging Trust

$23.38

0.86 (3.82%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Hot Stocks
RLJ Lodging Trust announces sale of two hotels in NYC for $286M »

RLJ Lodging Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEIC

SEI Investments

$48.16

1.2 (2.56%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Hot Stocks
SEI Investments signs three-year contract extension with Veritas Investment »

SEI UK Private Banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUE

Nucor

$65.10

2.07 (3.28%)

09:02
12/06/16
12/06
09:02
12/06/16
09:02
Hot Stocks
Nucor to acquire Southland Tube for $130M »

Nucor announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSTX

Mast Therapeutics

$0.08

0.0009 (1.08%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Hot Stocks
Mast Therapeutics enrolls first patient in Phase 2 study of AIR001 »

Mast Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$27.21

-1.17 (-4.12%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Upgrade
Consolidated Communications rating change  »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NLSN

Nielsen

$42.41

0.34 (0.81%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Conference/Events
Nielsen to host 2016 analyst day »

2016 Analyst Day to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

CMG

Chipotle

$396.27

-3.76 (-0.94%)

09:00
12/06/16
12/06
09:00
12/06/16
09:00
Hot Stocks
Chipotle says sales haven't recovered as much as previously expected »

Says "took eye off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

RGSE

Real Goods Solar

$0.51

0.0596 (13.23%)

09:00
12/06/16
12/06
09:00
12/06/16
09:00
Syndicate
Breaking Syndicate news story on Real Goods Solar »

Real Goods Solar files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
12/06/16
12/06
09:00
12/06/16
09:00
General news
U.S. trade deficit widened 17.8% to -$42.6 B in October »

U.S. trade deficit…

REI

Ring Energy

$12.15

-0.81 (-6.25%)

08:59
12/06/16
12/06
08:59
12/06/16
08:59
Syndicate
Ring Energy 6.5M share Spot Secondary priced at $11.50 »

SunTrust and Seaport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NSTG

NanoString

$21.99

-0.15 (-0.68%)

08:59
12/06/16
12/06
08:59
12/06/16
08:59
Recommendations
NanoString analyst commentary  »

NanoString a top growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

T

AT&T

$38.63

0.02 (0.05%)

, TWX

Time Warner

$93.34

-0.46 (-0.49%)

08:57
12/06/16
12/06
08:57
12/06/16
08:57
Hot Stocks
AT&T CEO says Time Warner review should be 'straightforward' »

Says Time Warner (TWX)…

T

AT&T

$38.63

0.02 (0.05%)

TWX

Time Warner

$93.34

-0.46 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

08:56
12/06/16
12/06
08:56
12/06/16
08:56
General news
Redbook Store Sales data reported »

Week of 12/3 Redbook…

TDOC

Teladoc

$18.45

0.5 (2.79%)

08:55
12/06/16
12/06
08:55
12/06/16
08:55
Hot Stocks
Teladoc says reached 100,000 telehealth visits during November »

Teladoc announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.